Abstracts tagged "Microscopic Polyangiitis"

Abstract Number: 2375 • ACR Convergence 2023
Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7
Shoichi Fukui¹, Haruna Matsuo², Kanako Kojima³, Shota Kurushima¹, Tohru Michitsuji⁴, Yoshika Tsuji⁵, Toshimasa Shimizu³, Masataka Umeda³, Remi Sumiyoshi⁵, Takashi Igawa¹, Tomohiro Koga⁵, Shin-ya Kawashiri¹, Naoki Iwamoto¹, Tomoki Origuchi¹ and Atsushi Kawakami¹, ¹Nagasaki University, Nagasaki, Japan, ²Nagasaki University, Nagasaki City, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: Interleukin 7 (IL-7) is a hematopoietic growth factor produced by stromal cells in the bone marrow and thymus, which is indispensable in maintaining immune…
Abstract Number: 2376 • ACR Convergence 2023
Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis
Teppei Hashimoto¹, Kazuteru Noguchi², Yuko Minagawa², Takeo Abe², Masao Tamura², Tetsuya Furukawa¹, Naoto Azuma² and Kiyoshi Matsui¹, ¹Hyogo Medical University, Nishinomiya, Japan, ²Hyogo Medical University, School of Medicine, Nishinomiya, Japan
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening disease requiring complex management due to a lack of suitable biomarkers. Elevated or persistently positive…
Abstract Number: 2379 • ACR Convergence 2023
A Real-World Descriptive Study of Renal Outcomes Among Patients with ANCA-Associated Vasculitis Initiating Remission Induction Therapy
Sam Oh¹, Sushmitha Inguva², Pallavi Rane² and Brian Tumminello³, ¹Amgen, Inc., South San Francisco, CA, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Inc., San Juan Capistrano, CA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases characterized by inflammation and necrosis of small- to medium-sized blood vessels, commonly affecting the…
Abstract Number: 2380 • ACR Convergence 2023
Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Chan-Bum Choi¹, Jung-Min Shin², Nayeon Choi³ and Soorack Ryu³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…
Abstract Number: 2385 • ACR Convergence 2023
Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis
Jon Idoate¹, Morgane Mourguet¹, Thomas Villeneuve¹, Grégoire Prevot¹, Laurent Guilleminault², Ribes David¹, Stan Faguer¹, Antoine Huart¹, Dominique Chauveau¹, Laurent Alric¹, Martin Michaud¹, Laurent Sailler¹, Sébastien De Almeida Chavez¹, Emmanuelle Mouchon¹, Olivier Lairez¹ and Gregory Pugnet³, ¹CHU Toulouse, Toulouse, France, ²Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, ³CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France
Background/Purpose: The aim of this study was to investigate the risk of major adverse cardiovascular events (MACE) in patients with ANCA-associated vasculitis (AAV). Methods: We…
Abstract Number: 0681 • ACR Convergence 2023
Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis
Itay Marmor¹, Katelin Nickel², Matthew Keller², Guy Hazan³, Kevin Baszis⁴, Anthony French⁵ and Mary Hartman², ¹Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ²Washington University in St. Louis, St. Louis, MO, ³Soroka University Medical Center, Beer Sheva, Israel, ⁴Washington Univ in St. Louis School of Medicine, St. Louis, MO, ⁵Washington University School of Medicine, St. Louis, MO
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), often manifests with life-threatening complications. Cyclophosphamide (CYC) and rituximab…
Abstract Number: 0684 • ACR Convergence 2023
Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Ulrich Specks¹, David Jayne² and Peter Merkel³, ¹Mayo Clinic, Rochester, MN, ²University of Cambridge, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although respiratory tract involvement in ANCA-associated vasculitis (AAV) is frequent and associated with increased mortality, studies focusing on diffuse alveolar hemorrhage (DAH) in AAV…
Abstract Number: 0685 • ACR Convergence 2023
Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
Duvuru Geetha¹, Anisha Dua², Huibin Yue³, Carlo Salvarani⁴, David Jayne⁵ and Peter Merkel⁶, ¹Johns Hopkins University, Baltimore, MD, ²Northwestern University, Chicago, IL, ³Amgen, Inc., Thousand Oaks, CA, ⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: The randomized, double-blind, double-dummy, controlled Phase 3 ADVOCATE trial tested whether avacopan, an oral selective C5a receptor inhibitor approved for the treatment of ANCA-associated…
Abstract Number: 0686 • ACR Convergence 2023
Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
David Jayne¹, Duvuru Geetha², Christian Pagnoux³, Sebastian Sattui⁴ and Peter Merkel⁵, ¹University of Cambridge, Cambridge, United Kingdom, ²Johns Hopkins University, Baltimore, MD, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Older adults are at increased risk of glucocorticoid (GC)-related toxicity; minimization of GCs is a major focus for treatment of patients with ANCA-associated vasculitis…
Abstract Number: 0436 • ACR Convergence 2022
Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study
Julien Culerrier¹, Yann Nguyen², Omer Karadag³, Sule Yasar Bilge⁴, Tuba DEMIRCI YILDIRIM⁵, Tahir Saygin Öğüt⁶, Veli Yazisiz⁶, Cemal Bes⁷, Ayse Cefle⁸, Oznur Sadioglu Cagdas⁹, Ayten Yazici⁸, Andreas Kronbichler¹⁰, David Jayne¹⁰, Alexis Regent¹¹, Vitor Teixeira¹², Sylvain Marchand-Adam¹³, PIerre Duffau¹⁴, Saskia Oro¹⁵, Baptiste Andre¹⁶, Luminita Luca¹⁷, Sarah Lechtman¹⁸, Achille Aouba¹⁹, Celine Lebas²⁰, Amélie Servettaz²¹, Amandine Dernoncourt²², Marc Ruivard²³, Anne-Marie Milesi²⁴, Vincent Poindron²⁵, Patrick Jego²⁶, Roberto Padoan²⁷, Paolo Delvino²⁸, Frédéric Vandergheynst²⁹, Christian Pagnoux³⁰, Elaine Yacyshyn³¹, Peter Lamprecht³², Oliver Flossmann³³, Xavier Puéchal¹¹ and Benjamin Terrier¹¹, ¹Université Paris Cité, Paris, France, Paris, France, ²AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, ³Hacettepe University, Ankara, Turkey, ⁴Eskişehir Osmangazi Üniversity, Eskisehir, Turkey, ⁵Dokuz Eylul University, İzmir, Turkey, ⁶Akdeniz University, Antalya, Turkey, ⁷Bahçeşehi University, Istanbul, Turkey, ⁸Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, ⁹Kocaeli University, Kocaeli, Turkey, ¹⁰University of Cambridge, Cambridge, United Kingdom, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ¹²Hospital de Faro, CHUA, Lisbon, Portugal, ¹³Tours University Hospital, Tours, France, ¹⁴CHU Bordeaux, Bordeaux, France, ¹⁵Assistance Publique - Hôpitaux de Paris., Paris, France, ¹⁶Hôpital de la Timone, Marseille, Marseille, France, ¹⁷CHU de Poitiers, Poitiers, France, ¹⁸CHU Nice, Nice, France, ¹⁹Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ²⁰CHRU Lille, Lille, France, ²¹CHU Reims, Reims, France, ²²CHU Amiens - Picardie, Amiens, France, ²³Clermont Ferrand University Hospital, Clermont-Ferrand, France, ²⁴Centre hospitalier de Vichy, Vichy, France, ²⁵Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁶CHU Rennes, Paris, France, ²⁷University of Padova, Padova, Italy, ²⁸Università di Pavia, Vercelli, Italy, ²⁹Professeur de Médecine Interne et Sémiologie médicale, Directeur de la Clinique de Médecine Interne Générale, Université Libre de Bruxelles, Bruxelles, France, ³⁰Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³¹University of Alberta, Edmonton, AB, Canada, ³²Department of Rheumatology University of Lübeck Ratzeburger Allee, Lübeck, Germany, ³³Royal Berkshire Hospital, Reading, United Kingdom
Background/Purpose: ANCA-associated vasculitides (AAV) induced by anti-thyroid drugs (ATD) is a well-known entity. However, characteristics, requirement for immunosuppressive agents and the risk of relapse remain…
Abstract Number: 0439 • ACR Convergence 2022
Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles
Lynn Fussner¹, David Cuthbertson², Peter Grayson³, David Jayne⁴, Carol McAlear⁵, Michael Walsh⁶, Katherine Siminovitch⁷, Ulrich Specks⁸ and Peter Merkel⁹, ¹The Ohio State University, Columbus, OH, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: There are multiple reasons to suspect that alpha-1 antitrypsin (A1AT) genotype impacts disease characteristics in ANCA-associated vasculitis (AAV). A1AT serves as the predominant endogenous…
Abstract Number: 0442 • ACR Convergence 2022
Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
Lilian Xu¹, Faten Aqeel¹, Ojaswi Tomar², Tingting Li² and Duvuru Geetha¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Washington University in St. Louis School of Medicine, St. Louis, MO
Background/Purpose: Therapies for ANCA-associated vasculitis (AAV) have evolved over the last 3 decades. In light of new data on plasma exchange (PLEX) and glucocorticoid (GC)…
Abstract Number: 0453 • ACR Convergence 2022
Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis
Aman Sharma¹, Prateek Deo¹, Shankar Naidu², Joydeep Samanta³, Sakshi Mittal³, Kusum Sharma³, Ritambhra Nada³, Varun Dhir⁴, sanjay jain² and Ranjana Minz², ¹PGIMER, Chandigarh, India, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³PGIMER, Chandigarh, India, ⁴PGIMER, CHD, INDIA, Chandigarh, India
Background/Purpose: The purpose of this study was to validate the recently published 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for…
Abstract Number: 0457 • ACR Convergence 2022
A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis
Jan Schirmer¹, Beatriz Sanchez-Alamo², Sara Monti³, Bernhard Hellmich⁴, David Jayne⁵ and Gunnar Tomasson⁶, ¹University Medical Center Schleswig-Holstein, Kiel, Germany, ²Lund University, Skåne University Hospital, Lund, Sweden, ³Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ⁴Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Centre for Rheumatology Research, University Hospital Reykjavik, Reykjavik, Iceland
Background/Purpose: Since the publication of the 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV), the publication of…
Abstract Number: 0526 • ACR Convergence 2022
Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial
Lynn Fussner¹, Luis Felipe Flores-Suarez², Rodrigo Cartin-Ceba³, Ulrich Specks³, P. Gerard Cox⁴, David Jayne⁵, Peter Merkel⁶ and Michael Walsh⁴, ¹The Ohio State University, Columbus, OH, ²Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, ³Mayo Clinic, Rochester, MN, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].